Author

Feng Xu

OpenAlex ID: A5020050141

A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors (MANTRA-2).

2022 · Ecaterina Elena Dumbrava, Glenn J. Hanna, et al. · Journal of Clinical Oncology · 7

Using CDKN2A loss in the context of wildtype TP53 to predict sensitivity for the MDM2 inhibitor milademetan.

2022 · Vijaya G Tirunagaru, Feng Xu, et al. · Journal of Clinical Oncology

Works count: 2

Citation count: 7

H-index: 1

I10-index: